TES-1025 is the first potent and selective inhibitor of human ACMSD (IC50 = 0.013 μM) that increases NAD+ levels in cellular systems. Defects in NAD+ homeostasis underpin a wide range of diseases, including cancer, metabolic disorders, and aging. References: Pellicciari R, Liscio P, Giacchè N, De Franco F, Carotti A, Robertson J, Cialabrini L, Katsyuba E, Raffaelli N, Auwerx J. α-Amino-β-carboxymuconate-ε-semialdehyde Decarboxylase (ACMSD) Inhibitors as Novel Modulators of De Novo Nicotinamide Adenine Dinucleotide (NAD(+)) Biosynthesis. J Med Chem. 2018 Jan 26. doi: 10.1021/acs.jmedchem.7b01254. [Epub ahead of print] PubMed PMID: 29345930.

纯度：≥98%

CAS：1883602-21-8